Cetera Investment Advisers Grows Holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Cetera Investment Advisers raised its position in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 22.7% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 23,358 shares of the medical equipment provider's stock after purchasing an additional 4,320 shares during the period. Cetera Investment Advisers' holdings in Lantheus were worth $2,090,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Kestra Investment Management LLC purchased a new position in Lantheus in the 4th quarter valued at about $27,000. Summit Securities Group LLC purchased a new position in shares of Lantheus during the 4th quarter worth about $37,000. UMB Bank n.a. lifted its holdings in shares of Lantheus by 31.5% during the 4th quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider's stock worth $50,000 after acquiring an additional 134 shares during the period. Parkside Financial Bank & Trust lifted its holdings in shares of Lantheus by 49.4% during the 4th quarter. Parkside Financial Bank & Trust now owns 847 shares of the medical equipment provider's stock worth $76,000 after acquiring an additional 280 shares during the period. Finally, 1620 Investment Advisors Inc. purchased a new position in shares of Lantheus during the 4th quarter worth about $125,000. 99.06% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Lantheus

In other Lantheus news, Director Mary Anne Heino sold 53,107 shares of the stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $94.35, for a total value of $5,010,645.45. Following the completion of the sale, the director now owns 440,399 shares of the company's stock, valued at $41,551,645.65. This trade represents a 10.76% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Robert J. Jr. Marshall sold 10,000 shares of the stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $100.52, for a total transaction of $1,005,200.00. Following the completion of the sale, the chief financial officer now directly owns 113,860 shares of the company's stock, valued at $11,445,207.20. This trade represents a 8.07% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 63,109 shares of company stock worth $6,016,046. Company insiders own 1.50% of the company's stock.

Lantheus Stock Performance

NASDAQ LNTH opened at $81.24 on Monday. Lantheus Holdings, Inc. has a one year low of $75.00 and a one year high of $126.89. The company's 50 day moving average price is $97.11 and its 200 day moving average price is $93.08. The firm has a market capitalization of $5.62 billion, a price-to-earnings ratio of 13.52 and a beta of 0.23.

Lantheus (NASDAQ:LNTH - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The medical equipment provider reported $1.53 EPS for the quarter, missing the consensus estimate of $1.64 by ($0.11). Lantheus had a net margin of 28.57% and a return on equity of 44.29%. The business had revenue of $372.76 million during the quarter, compared to analysts' expectations of $377.37 million. During the same quarter in the previous year, the business posted $1.69 EPS. The company's quarterly revenue was up .8% on a year-over-year basis. Sell-side analysts forecast that Lantheus Holdings, Inc. will post 6.01 EPS for the current fiscal year.

Analyst Ratings Changes

Several research analysts have recently weighed in on the stock. Truist Financial cut their price objective on shares of Lantheus from $127.00 to $117.00 and set a "buy" rating on the stock in a report on Thursday, May 8th. StockNews.com upgraded shares of Lantheus from a "hold" rating to a "buy" rating in a report on Thursday, May 8th. Finally, B. Riley cut their price objective on shares of Lantheus from $127.00 to $122.00 and set a "buy" rating on the stock in a report on Friday, March 21st. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has a consensus rating of "Buy" and a consensus target price of $132.67.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.